Susan G. Komen for the Cure Presentation at Partnering for Cures


Published on

Susan G. Komen for the Cure presents its research and development strategies at the 2009 Partnering for Cures conference in New York.

Published in: Health & Medicine
1 Like
  • Be the first to comment

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Susan G. Komen for the Cure Presentation at Partnering for Cures

  1. 1. Organization/History <ul><li>Founded on a promise between sisters in 1982 </li></ul><ul><li>Largest breast cancer organization in the world </li></ul><ul><ul><ul><li>122 Domestic Affiliates/3 International Affiliates </li></ul></ul></ul><ul><ul><ul><li>Outreach/Partnership in 50 countries </li></ul></ul></ul><ul><ul><ul><li>$370 million FY 09 consolidated revenues </li></ul></ul></ul><ul><ul><ul><li>250 corporate partners </li></ul></ul></ul><ul><ul><ul><li>134 Race for the Cure® series events w/1.6 million participants </li></ul></ul></ul>
  2. 2. Breast Cancer Disease Landscape <ul><li>Breast Cancer in 2009 </li></ul><ul><ul><li>192,370 new cases of invasive breast cancer </li></ul></ul><ul><ul><li>40,170 deaths from breast cancer </li></ul></ul><ul><li>Breast cancer is the most common cancer among women in the United States, other than skin cancer. It is the second leading cause of cancer death in women, after lung cancer. </li></ul><ul><li>The chance of a woman having invasive breast cancer some time during her life is a little less 1 in 8. </li></ul><ul><li>The chance of dying from breast cancer is about 1 in 35 . Breast cancer death rates have been going down. </li></ul><ul><li>Right now there are more than 2½ million breast cancer survivors in the United States. </li></ul>
  3. 3. Breast Cancer Market Landscape <ul><li>Worldwide, an estimated 1 million breast cancers will be identified this year. </li></ul><ul><li>This year, 500,000 new and existing patients will die from the disease. </li></ul><ul><li>  By 2020, 70 % of all breast cancer cases worldwide will be in developing countries. </li></ul><ul><li>We need: </li></ul><ul><ul><li>Better Screening Methods ( transportable, higher degree of specificity and sensivity) </li></ul></ul><ul><ul><li>Better Medicines ( more cost effective, targeted ) </li></ul></ul>
  4. 4. Research and Development Strategy <ul><li>Komen’s commitment to supporting life-saving research has never been stronger. Building on 27 years of funding research to find the causes and cures of breast cancer, Komen continues its important new focus on research that will speed the translation of discoveries into two areas: </li></ul><ul><ul><li>reductions in breast cancer mortality and/or incidence within the next decade , and </li></ul></ul><ul><ul><li>addressing disparities in breast cancer across populations . </li></ul></ul>
  5. 5. Research and Development Strategy <ul><li>Susan G. Komen for the Cure Tissue Bank </li></ul><ul><li>Screening: Technology Summit </li></ul><ul><li>Major Partnerships </li></ul><ul><ul><li>Triple Negative Breast Cancer Foundation (TNBC) </li></ul></ul><ul><ul><li>The Breast Cancer Research Consortium (TBCRC) </li></ul></ul><ul><li>Promise Grants </li></ul><ul><ul><li>Triple Negative Breast Cancer </li></ul></ul><ul><ul><li>Inflammatory Breast Cancer </li></ul></ul><ul><ul><li>Prevention </li></ul></ul>
  6. 6. Accomplishments to Date <ul><li>Causes of Breast Cancer: Komen Tissue Bank at IU </li></ul><ul><ul><li>Increased distribution of normal tissue samples </li></ul></ul><ul><ul><li>Create virtual tissue bank </li></ul></ul><ul><ul><li>Create “normal” cell lines </li></ul></ul><ul><li>Partnership Grants: TBCRC </li></ul><ul><ul><li>12 trials currently running </li></ul></ul><ul><ul><li>98% of patients accrue to trials at participating institutions </li></ul></ul><ul><li>Promise Grants: Moving from Bench to Bedside </li></ul><ul><ul><li>$20M invested in Prevention </li></ul></ul><ul><ul><li>TNBC moving to clinical trial </li></ul></ul><ul><ul><li>Inflammatory moving to clinical trial </li></ul></ul>
  7. 7. Budget <ul><li>Our comprehensive approach touches education, research, community support, advocacy </li></ul><ul><ul><ul><li>80% of funds raised devoted to mission </li></ul></ul></ul><ul><ul><ul><li>$1.5 billion invested in research/community since inception </li></ul></ul></ul><ul><ul><ul><li>$450 million total research budget </li></ul></ul></ul><ul><ul><ul><ul><li>Currently 650 grants totaling $260 million </li></ul></ul></ul></ul><ul><li>NEED $25M - $50M for new initiatives related to global screening advances and early stage clinical trials (targeted therapies) </li></ul><ul><li>4 Star Charity Navigator Rating </li></ul><ul><li>Komen funding has touched every major advance in breast cancer treatment </li></ul>
  8. 8. Leadership <ul><li>Ambassador Nancy G. Brinker, Founding Chair </li></ul><ul><li>Global Goodwill Ambassador for Cancer Control, World Health Organization </li></ul><ul><li>Presidential Medal of Freedom recipient 2009 </li></ul><ul><li>Former U.S. Chief of Protocol/Ambassador to Hungary </li></ul><ul><li>Eric P. Winer, MD, FACS, Chief Scientific Adviser </li></ul><ul><li>Leads SGK Scientific Advisory Board </li></ul><ul><li>Director, Breast Oncology Center, Dana Farber Cancer Center </li></ul><ul><li>Professor of Medicine, Harvard </li></ul><ul><li>Elizabeth Thompson, Vice President, Health Sciences </li></ul><ul><li>Leads Komen’s Research, Community Health, Public and Medical Affairs and Educational Portfolio </li></ul>
  9. 9. Scientific Advisory Board <ul><li>Melissa Bondy, Ph.D. professor of epidemiology at the University of Texas M.D. Anderson Cancer Center. </li></ul><ul><li>Powel Brown , M.D., Ph.D., chair of clinical cancer prevention, University of Texas M.D. Anderson Cancer Center. </li></ul><ul><li>H. Kim Lyerly, M.D. , George Barth Geller professor of research at Duke University, Durham, N.C.; director of the Duke Comprehensive Cancer Center and principal investigator of the Duke Specialized Program in Research Excellence (SPORE). </li></ul><ul><li>Amelie G. Ramirez, DrPH , chairman of Komen's National Hispanic/Latino Advisory Council, professor of epidemiology and biostatistics at the University of Texas Health Science Center at San Antonio (UTHSCSA) </li></ul><ul><li>George W. Sledge, M.D. , Ballve-Lantero professor of oncology and co-director of the breast cancer program at the Indiana University Melvin and Bren Simon Cancer Center. </li></ul><ul><li>Sara Sukumar, Ph.D. , professor of oncology and pathology and co-director of the breast cancer research program at the Sidney Kimmel Cancer Center at Johns Hopkins University School of Medicine in Baltimore. </li></ul><ul><li>Chris Tannous, Ph.D. , two-time breast cancer survivor, President and Public Policy Chair of the Orange County of Affiliate of Susan G. Komen for the Cure </li></ul>
  10. 10. Summary Points <ul><li>Track Record of Experience— we know the investigators, the science, and the opportunities </li></ul><ul><li>Innovative Portfolio- we’re investing in the key areas spanning screening, prevention, and the development of targeted therapeutics </li></ul><ul><li>Global Reach- we can leverage scientists, clinicians, and patients around the globe to change the face of breast cancer. </li></ul>
  11. 11. Questions and Answers <ul><li>Thank you for your interest! </li></ul><ul><li>Please contact me at: </li></ul><ul><ul><li>[email_address] </li></ul></ul><ul><ul><li>972-855-1638 </li></ul></ul>